http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2010105716-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_cf011dc072e5c64d21aa49c134fdc738 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4745 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P3-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4745 |
| filingDate | 2007-10-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_702792f9acf95674dce9ae776cf7d7f7 |
| publicationDate | 2010-04-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | US-2010105716-A1 |
| titleOfInvention | Camkk(beta) as a target for treating obesity |
| abstract | A method of treating a condition in a subject in need thereof, comprising administering a calcium/calmodulin dependency kinase kinase (CaMKK) inhibitor in a treatment-effective amount. Conditions which may be treated include obesity (particularly adult obesity), insulin resistance (including high fat diet-induced insulin resistance), hyperglycemia (including hyperglycemia accompanying obesity), diabetes, etc. |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9999620-B2 |
| priorityDate | 2006-10-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 618.